Industry
Drug Manufacturers - Specialty & Generic
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
June 20, 2024 | 5:26 pm
Portfolio Pulse from Avi Kapoor
June 20, 2024 | 2:21 pm
Portfolio Pulse from ryanfaloona@benzinga.com
June 20, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 11:10 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 3:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 5:52 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 2:11 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.